FBIO - Fortress Biotech, Inc.
| Previous Close | 1.60 |
| Open | 1.59 |
| Bid | 1.50 x 1800 |
| Ask | 1.77 x 1800 |
| Day's Range | 1.52 - 1.60 |
| 52 Week Range | 1.41 - 5.54 |
| Volume | 410,155 |
| Avg. Volume | 181,459 |
| Market Cap | 85.861M |
| Beta | 0.49 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.87 |
| Earnings Date | Aug 7, 2018 - Aug 13, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.67 |
- GlobeNewswire•10 days ago
Fortress Biotech Announces Publication of Preclinical Data on AAV-ATP7A Gene Therapy Combined with CUTX-101 (Copper Histidinate) for Menkes Disease in Molecular Therapy: Methods & Clinical Development
NEW YORK, Sept. 12, 2018-- Fortress Biotech, Inc., a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced the ...
- GlobeNewswire•16 days ago
Checkpoint Therapeutics Announces Encouraging Safety and Efficacy Data from Phase 1/2 Clinical Trial of EGFR Inhibitor CK-101
6 of 8 pts ORR in treatment-naïve EGFR mutation-positive NSCLC patients. Well-tolerated with unremarkable safety profile; No DLTs or related SAEs. Phase 3 trial in treatment-naïve EGFR mutation-positive ...
- GlobeNewswire•18 days ago
Mustang Bio Announces Presentations on CAR T Therapies at 4th Annual CAR-TCR Summit 2018
NEW YORK, Sept. 04, 2018-- Mustang Bio, Inc., a Fortress Biotech Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell technology ...
- GlobeNewswire•23 days ago
Checkpoint Therapeutics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
NEW YORK, Aug. 30, 2018-- Checkpoint Therapeutics, Inc., a Fortress Biotech company, today announced that James F. Oliviero, President and Chief Executive Officer of Checkpoint, will present a company ...
- GlobeNewswire•23 days ago
Mustang Bio to Participate in September Investor Conferences
NEW YORK, Aug. 30, 2018-- Mustang Bio, Inc., a Fortress Biotech Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell technology and ...
- GlobeNewswire•last month
National Holdings Corporation Announces Expansion of Capital Markets Team
NEW YORK, Aug. 20, 2018-- National Holdings Corporation, a leading full-service independent brokerage, investment banking, trading insurance accounting and asset management firm, today announced the expansion ...
- GlobeNewswire•last month
Avenue Therapeutics Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights
Company reported positive Phase 3 data in patients with post-surgical pain following bunionectomy. Initiation of second pivotal Phase 3 trial expected in the second half of 2018. NEW YORK, Aug. 14, 2018-- ...
- GlobeNewswire•last month
Mustang Bio Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights
NEW YORK, Aug. 13, 2018-- Mustang Bio, Inc., a Fortress Biotech Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell technology and ...
- GlobeNewswire•last month
Mustang Bio and St. Jude Children’s Research Hospital Enter into Exclusive Worldwide License Agreement for a Ground-Breaking, Clinical-Stage Lentiviral Gene Therapy with Curative Potential for X-linked Severe Combined Immunodeficiency
Mustang Bio, Inc. (“Mustang”) (MBIO), a Fortress Biotech (FBIO) Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR T) technology, and St. Jude Children’s Research Hospital (“St. Jude”), the nation’s leading hospital dedicated to understanding, treating and curing childhood cancer and other life-threatening diseases, announced today that they have partnered and entered into an exclusive worldwide license agreement for the development of a first-in-class ex vivo lentiviral gene therapy for the treatment of X-linked severe combined immunodeficiency (“X-SCID”), also known as bubble boy disease.
- GlobeNewswire•last month
Checkpoint Therapeutics Announces Clinical Data on EGFR Inhibitor CK-101 Selected for Late-Breaking Oral Presentation at IASLC 19th World Conference on Lung Cancer
NEW YORK, Aug. 13, 2018-- Checkpoint Therapeutics, Inc., a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for ...
- American City Business Journals•last month
St. Jude and Mustang Bio enter into exclusive worldwide license agreement
A partnership between St. Jude and Mustang Bio may change the challenges faced by those diagnosed with what is commonly referred to as “bubble boy disease.”
- Zacks•last month
Fortress Biotech (FBIO) Reports Q2 Loss, Tops Revenue Estimates
Fortress Biotech (FBIO) delivered earnings and revenue surprises of 25.37% and 30.46%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•last month
Fortress Biotech: 2Q Earnings Snapshot
The New York-based company said it had a loss of 50 cents per share. The biopharmaceutical company posted revenue of $63.8 million in the period. In the final minutes of trading on Thursday, the company's ...
- GlobeNewswire•last month
Fortress Biotech Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights
NEW YORK, Aug. 09, 2018-- Fortress Biotech, Inc., a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced financial ...
- GlobeNewswire•last month
Mustang Bio to Present at 10th Annual Bioprocessing Summit
NEW YORK, Aug. 09, 2018-- Mustang Bio, Inc., a Fortress Biotech Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell technology, ...
- GlobeNewswire•last month
Checkpoint Therapeutics Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights
NEW YORK, Aug. 07, 2018-- Checkpoint Therapeutics, Inc., a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for ...
- GlobeNewswire•2 months ago
Fortress Biotech Announces Aevitas Therapeutics Enters Sponsored Research Agreement with the University of Pennsylvania to Advance AAV Gene Therapy Technology
NEW YORK, Aug. 06, 2018-- Fortress Biotech, a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced that its ...
- Reuters•2 months ago
Special Report: Biotech incubator taps investors through in-house brokerage
Last August, National Securities Corp analyst Jonathan Aschoff was bullish on Avenue Therapeutics Inc (ATXI.O), a fledgling biotechnology company with no revenue and one drug in clinical trials. Nearly a year later, Avenue shares are down 36 percent, at about $4. A few months earlier, Aschoff had waxed equally optimistic about another biotech venture, Checkpoint Therapeutics Inc (CKPT.O), with several cancer drugs in various stages of development.
- GlobeNewswire•2 months ago
National Holdings Appoints Henry E. Kaplan as President and Chief Operating Officer of National Asset Management
National Holdings Corporation (NHLD) (“National” or the “Company”), a leading full-service independent brokerage, investment banking, trading, insurance, accounting and asset management firm, today announced the appointment of Henry E. Kaplan as President and Chief Operating Officer of National Asset Management, Inc., as well as Executive Vice President, Investment Solutions at National Securities Corporation. Mr. Kaplan brings over thirty years of industry experience, most recently as a Managing Director at Morgan Stanley, where he transformed the wealth management platform into an industry leading consulting and advisory business.
- GlobeNewswire•2 months ago
Mustang Bio Completes Pre-IND Meeting with FDA for MB-102 (CD123 CAR T)
Mustang Bio, Inc. (“Mustang”) (MBIO), a Fortress Biotech (FBIO) Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR T) technology, announced today that it has completed a pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) for MB-102 (CD123 CAR T). MB-102 is a CAR T therapy in development for the treatment of acute myeloid leukemia (AML), blastic plasmacytoid dendritic cell neoplasm (BPDCN) and high-risk myelodysplastic syndrome (MDS).
- GlobeNewswire•3 months ago
Fortress Biotech Announces Cyprium Therapeutics’ CUTX-101 (Copper Histidinate) Granted FDA Fast Track Designation for Treatment of Classic Menkes Disease
As a subsidiary of Fortress, Cyprium is developing CUTX-101 for Menkes disease under a Cooperative Research and Development Agreement (CRADA) with the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), part of the National Institutes of Health (NIH). The CRADA was established in March 2017.
- GlobeNewswire•3 months ago
Caelum Biosciences Announces Complete Cardiac Data Analysis from Phase 1b Trial of CAEL-101 in AL Amyloidosis
Nine of 10 cardiac patients on CAEL-101 showed improvement in global longitudinal strain. CAEL-101 led to sustained decrease in NT-proBNP levels. Data presented at American Society of Echocardiography ...
- GlobeNewswire•3 months ago
Mustang Bio Added to Russell 2000®, 3000® and Microcap® Indexes
NEW YORK, June 25, 2018-- Mustang Bio, Inc., a Fortress Biotech Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell technology, ...
